3. Comparative Analysis Of The Expression Level Of Alphaphetoprotein With A Stage And Grade Of Hepatocellular Carcinoma

Authors

  • B.K. Issamatov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan, NCJSC “Kazakh national medical universitynamed after S.D.Asfendiyarov”, Almaty, Kazakhstan
  • B.B. Baimakhanov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • U.Sh. Medeubekov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • A.T. Chormanov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • E.A. Yenin JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • I.Y. Sagatov JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • T.K. Tajibaev JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • E.M. Musanova JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan
  • E.T. Akmyrzaev JSC «National Scientific Center of Surgery named after A.N. Syzganov», Almaty, Kazakhstan

Downloads

Abstract

Hepatocellular carcinoma, a malignant neoplasm originating from hepatocytes, is the most common type of primary liver cancer. In recent years, there has been an increase in the incidence rate of hepatocel-lular carcinoma worldwide, including in Kazakhstan. Currently, diagnostic issues are still important. The article describes the analysis of the expression of alpha-fetoprotein in comparison with the stage and grade of hepatocellular carcinoma. try, stage, grade

Keywords

hepatocellular carcinoma, alpha-fetoprotein, immunohistochemis-try, stage

References

  1. World Health Organaization. Cancer. Accessed 16 April 2017. http://www.who.int/mediacentre/fact-sheets/fs297/en/
  2. European Association For The Study of the Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinicalpracticeguidelines: managementofhepatocellularcarcinoma. J Hepatol 2012;56:908–943. PMID: 22424438 DOI:10.1016/j.jhep.2011.12.001[IndexedforMEDLINE]
  3. Masao Omata, Ann-Lii Cheng, NorihiroKokudo et al. Asia–Pacific clinical practice guidelines on the man-agement of hepatocellular carcinoma: a 2017 update. HepatolInt 2017; 11:317–370. PMCID: PMC5491694 DOI:10.1007/s12072-017-9799-9[IndexedforMED-LINE]
  4. F. Bray; J. Ferlay; I. Soerjomataramet al. Global Can-cer Statistics 2018: GLOBOCAN Estimatesof Inci-dence and Mortality Worldwide for 36 Cancersin 185 Countries. CA CANCER J CLIN 2018;68:394–424. PMID: 30207593, DOI:10.3322/caac.21492[IndexedforMEDLINE]
  5. Global Cancer Statistics 2018: GLOBOCAN, https:// gco.iarc.fr/today/home
  6. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best PractRes-ClinGastroenterol. 2005 Feb;19(1):3-23. PMID: 15757802 DOI:10.1016/j.bpg.2004.10.004[IndexedforMEDLINE]
  7. Edamoto Y, Hara A, Biernat W, et al. Alterationsof RB1, p53 andWntpathwaysinhepatocellularcarcinomasas-sociatedwithhepatitis C, hepatitis B andalcoholi-clivercirrhosis. Int J Cancer. 2003 Sep1;106(3):334-41. PMID: 12845670 DOI:10.1002/ijc.11254[IndexedforMEDLINE]
  8. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res ClinGastro-enterol. 2014; 28: 753-770. PMID: 25260306 DOI:10.1016/j.bpg.2014.08.007[IndexedforMEDLINE]
  9. Issamatov B.K., Baimakhanov B.B., Zholdybay Zh.Zh., Medeubekov U.Sh., Chormanov A.T., Ta-jibaev T.K., Kaniev Sh.A., Sagatov I.Y., Moskalenko N.I., Shmonin V.M.«Statistical indicators analysis of primary liver cancer in the Republic of Kazakhstan»
  10. Kulik LM, Chokechanachaisakul A. Evaluation and management of hepatocellular carcinoma. Clin Liver Dis. 2015; 19: 23-43. PMID: 25454295 DOI:10.1016/j.cld.2014.09.002[IndexedforMEDLINE]
  11. SHchegolev AI, Mishnyov OD Rol’ immunogistohimi-cheskogoissledovaniyadlyadiagnostikigepatocellyu-lyarnojkarcinomy // Mezhdunarodnyjzhurnalprikladny hifundamental’nyhissledovanij= International Journal of Applied and Basic Research. 2017; 2:37 – 41 (In Russ)
  12. Tuffakha MS, Hychka SG , Husky GL. Immunokh-istokhimicheskaya diagnostika opukholej [Im-munohistochemical diagnosis of tumors]. Kyiv: Intermed;2013.P. 223
  13. RodionovSYu,Cherkasov VA, Malyutina NN, Orlov OA, (2004) Alfa-fetoprotein [Alfa-fetoprotein]. Ekat-erynburh: UrO RAN;
  14. Johnson PJ: Role of alpha-fetoprotein in the diag-nosis and management of hepatocellular carcinoma. J GastroenterolHepatol 1999, 14: 32 –
  15. Kateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M: Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int. 2008, 2: 17 –
  16. Yuen MF, Lai CL. Serological markers of liv-er cancer. Best Pract Res ClinGastroenterol. 2005;19:91–9.PMID:15757806 DOI:10.1016/j.bpg.2004.10.003[IndexedforMEDLINE]

Published

2020-04-01

Issue

No. 1 (2020)

Section

Статьи